The Fox Chase Chemical Diversity Center, Inc. (FCCDC)
is a company focused on providing medicinal chemistry/chemical biology support to basic research programs. Our goal is to assist researchers to develop their fundamental research into bona fide drug discovery programs.
We do this through a variety of means:
- Seek, find and develop molecular probes to better elucidate their target and potential therapeutic application.
- Advance Hits from screening to Lead status, using in silico design and chemical synthesis via small directed libraries or individual compounds; improve/develop structural activity relationships (SAR) as well as evaluate/improve ADME properties.
- Determine the Intellectual Property position of the chemical matter and provide a path forward for which novel compositions can be made and protected.
At FCCDC, we have >125 years of industrial experience ranging from big pharma (J&J, Merck), biotech and contract research organizations.
Here is a partial list of therapeutic areas and target classes studied over our careers:
- Central nervous system, neurology and psychiatry
- Anti-infectives (antibacterial and antiviral)
- Inflammation and immunology
- Diabetes and obesity, multiple targets
- Ion channels (IKr, Iks, nAChRs)
- GPCRs (integrins, avb3, 5-HT, dopamine, adrenergic)
- Kinases (Raf, p38, DAPK)
FCCDC is located in the PA Center for Drug Discovery at the PA Biotechnology Center (PBC) of Bucks County in Doylestown, Pennsylvania (just north of Philadelphia). The PBC is a 112,000 square foot campus that houses nonprofit research organizations and commercial start-up companies in the same facility.
Our laboratory space is fully equipped to meet our synthesis and analysis needs:
- 300 MHz NMR, multinuclear probe capability
- LC/MS and LC/MS/MS
- Microwave synthesizer (MAOS)
- Multiple chromatography systems
- Fully equipped labs: glassware, balances, vacuum pumps, ovens, platform shakers, pipettors, etc.
- Access to all other equipment of the PCDD and PBC